Effect of subtype-selective adenosine receptor antagonists on basal or haloperidol-regulated striatal function: Studies of exploratory locomotion and c-Fos immunoreactivity in outbred and A2AR KO mice

Behavioural Brain Research

Volumn 247, Issue , 2013, Pages 217-226

  Pardo, M ^a   Lopez Cruz L ^a   Valverde, O ^b   Ledent, C ^c   Baqi, Y ^d   Muller C E ^d   Salamone, J D ^e   Correa, M ^a,e  

^a UNIVERSITAT JAUME I   (Spain)

^b UNIVERSITAT POMPEU FABRA   (Spain)

^c UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^d UNIVERSITY OF BONN   (Germany)

^e UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Accumbens; Behavioral activation; Dopamine; Psychomotor slowing; Theophylline

Indexed keywords

8 CYCLOPENTYLTHEOPHYLLINE; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR ANTAGONIST; ADENOSINE RECEPTOR BLOCKING AGENT; HALOPERIDOL; MSX 3; PROTEIN C FOS; THEOPHYLLINE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; BRAIN FUNCTION; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; DRUG MECHANISM; IMMUNOREACTIVITY; KNOCKOUT MOUSE; LOCOMOTION; MALE; MOUSE; NONHUMAN; OPEN FIELD BEHAVIOR; OPEN FIELD TEST; OUTBRED STRAIN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSYCHOMOTOR PERFORMANCE; REARING;

ANIMALS; BEHAVIOR, ANIMAL; CORPUS STRIATUM; DOPAMINE ANTAGONISTS; EXPLORATORY BEHAVIOR; HALOPERIDOL; LOCOMOTION; MALE; MICE; MICE, KNOCKOUT; MOTOR ACTIVITY; PROTO-ONCOGENE PROTEINS C-FOS; PURINERGIC P1 RECEPTOR ANTAGONISTS; RECEPTOR, ADENOSINE A2A; RECEPTORS, DOPAMINE D2;

EID: 84876806918     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2013.03.035     Document Type: Article

References (83)

1. Kelley A.E. Locomotor activity and exploration. Behavioral neuroscience. A practical approach 1993, Oxford University Press, Oxford. A. Sahgal (Ed.).
2. Fishman R.H., Feigenbaum J.J., Yanai J., Klawans H.L. The relative importante of dopamine and norepinephrine in mediating locomotor activity. Progress in Neurobiology 1983, 20:55-88.
3. Kelly P.H., Iversen S.D. Selective 6-OHDA-induced destruction of mesolimbic dopamine neurons: abolition of psychostimulant-induced locomotor activity in rats. European Journal of Pharmacology 1976, 40:45-56.
4. Salamone J.D. Dopaminergic involvement in activational aspects of motivation: effects of haloperidol on schedule induced activity, feeding and foraging in rats. Psychobiology 1988, 16:196-206.
5. McCullough L.D., Salamone J.D. Involvement of nucleus accumbens dopamine in the motor activity induced by periodic food presentation: a microdialysis and behavioral study. Brain Research 1992, 592:29-36.
6. Hooks M.S., Kalivas P.W. The role of mesoaccumbens-pallidal circuitry in novelty-induced behavioral activation. Neuroscience 1995, 64:587-597.
7. Correa M., Carlson B.B., Wisniecki A., Salamone J.D. Nucleus accumbens dopamine and work requirements on interval schedules. Behavioural Brain Research 2002, 137:179-187.
8. Correa M., Wisniecki A., Betz A., Dobson D.R., O'Neill M.F., O'Neill M.J., et al. The adenosine A2A antagonist KF17837 reverses the locomotor suppression and tremulous jaw movements induced by haloperidol in rats: possible relevance to parkinsonism. Behavioural Brain Research 2004, 148:47-54.
9. Molloy AG, O'Boyle KM, Pugh MT, Waddington JL. Locomotor behaviors in response to new selective D-1 and D-2 dopamine receptor agonists, and the influence of selective antagonists. Pharmacology Biochemistry and Behavior 19986;25:249-3.
10. Starr B.S., Starr M.S. Differential effects of dopamine D1 and D2 agonists and antagonists on velocity of movement, rearing and grooming in the mouse. Implications for the roles of D1 and D2 receptors. Neuropharmacology 1986, 25:455-463.
11. Salamone J.D. The actions of neuroleptic drugs on appetitive instrumental behaviors. Handbook of psychopharmacology 1987, Plenum Press, New York. L.L. Iversen, S.D. Iversen, S.H. Snyder (Eds.).
12. Randall P.A., Pardo M., Nunes E.J., López Cruz L., Vemuri V.K., Makriyannis A., et al. Dopaminergic modulation of effort-related choice behavior as assessed by a progressive ratio chow feeding choice task: pharmacological studies and the role of individual differences. PLoS ONE 2012, 7:e47934.
13. Koob G.F., Riley S.J., Smith S.C., Robbins T.W. Effects of 6-hydroxydopamine lesions of the nucleus accumbens septi and olfactory tubercle on feeding, locomotor activity, and amphetamine anorexia in the rat. Journal of Comparative and Physiological Psychology 1978, 92:917-927.
14. Robbins T.W., Roberts D.C., Koob G.F. Effects of d-amphetamine and apomorphine upon operant behavior and schedule-induced licking in rats with 6-hydroxydopamine-induced lesions of the nucleus accumbens. Journal of Pharmacology and Experimental Therapeutics 1983, 224:662-673.
15. Kelley A.E., Gauthier A.M., Lang C.G. Amphetamine microinjections into distinctstriatal subregions cause dissociable effects on motor and ingestive behavior. Behavioural Brain Research 1989, 35:27-39.
16. Antoniou K., Kafetzopoulos E., Papadopoulou-Daifoti Z., Hyphantis T., Marselos M. D-amphetamine, cocaine and caffeine: a comparative study of acute effects on locomotor activity and behavioural patterns in rats. Neuroscience and Biobehavioral Reviews 1998, 23:189-196.
17. Ferré S., Fredholm B.B., Morelli M., Popoli P., Fuxe K. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends in Neurosciences 1997, 20:482-487.
18. Hauber W. Involvement of basal ganglia transmitter systems in movement initiation. Progress in Neurobiology 1998, 56:507-540.
19. Svenningsson P., Le Moine C., Fisone G., Fredholm B.B. Distribution, biochemistry and function of striatal adenosine A2A receptors. Progress in Neurobiology 1999, 59:355-396.
20. Schiffmann S.N., Jacobs O., Vanderhaeghen J.J. Striatal restricted adenosine A2A receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study. Journal of Neurochemistry 1991, 57:1062-1071.
21. Ferré S., O'Connor W.T., Fuxe K., Ungerstedt U. The striatopallidal neuron: a main locus for adenosine-dopamine interactions in the brain. Journal of Neuroscience 1993, 13:5402-5406.
22. Svenningsson P., Le Moine C., Kull B., Sunahara R., Bloch B., Fredholm B.B. Cellular expression of adenosine A2A receptor messenger RNA in the rat central nervous system with special reference to dopamine innervated areas. Neuroscience 1997, 80:1171-1185.
23. Pinna A., Wardas J., Simola N., Morelli M. New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonists. Life Sciences 2005, 77:3259-3267.
24. Fastbom J., Pazos A., Probst A., Palacios J.M. Adenosine A1 receptors in the human brain: a quantitative autoradiographic study. Neuroscience 1987, 22:827-839.
25. Fastbom J., Pazos A., Palacios J.M. The distribution of adenosine A1 receptors and 5'-nucleotidase in the brain of some commonly used experimental animals. Neuroscience 1987, 22:813-826.
26. Daly J.W., Fredholm B.B. Caffeine-an atypical drug of dependence. Drug and Alcohol Dependence 1998, 51:199-206.
27. Karcz-Kubicha M., Antoniou K., Terasma A., Quarta D., Solinas M., Justinova Z., et al. Involvement of adenosine A1 and A2A receptors in the motor effects of caffeine after its acute and chronic administration. Neuropsychopharmacology 2003, 28:1281-1291.
28. Antoniou K., Papadopoulou-Daifoti Z., Hyphantis T., Papathanasiou G., Bekris E., Marselos M., et al. A detailed behavioral analysis of the acute motor effects of caffeine in the rat: involvement of adenosine A1 and A2A receptors. Psychopharmacology 2005, 183:154-162.
29. Marston H.M., Finlayson K., Maemoto T., Olverman H.J., Akane A., Sharkey J., et al. Pharmacological characterization of a simple behavioral response mediated selectively by central adenosine A1 receptors, using in vivo and in vitro techniques. Journal of Pharmacology and Experimental Therapeutics 1998, 285:1023-1030.
30. Popoli P., Reggio R., Pèzzola A., Fuxe K., Ferré S. Adenosine A1 and A2A receptor antagonists stimulate motor activity: evidence for an increased effectiveness in aged rats. Neuroscience Letters 1998, 251:201-204.
31. Nagel J., Shladebach H., Kock M., Schwienbacher I., Müller C.E., Hauber W. Effects of an adenosine A2A receptor blockade in the nucleus accumbens on locomotion, feeding, and prepulse inhibition in rats. Synapse 2003, 49:279-286.
32. Collins L.E., Galtieri D.J., Collins P., Jones S.K., Port R.G., Paul N.E., et al. Interactions between adenosine and dopamine receptor antagonists with different selectivity profiles: Effects on locomotor activity. Behavioural Brain Research 2010, 211:148-155.
33. Chen J.F., Xu K., Petzer J.P., Staal R., Xu Y.H., Beilstein M. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. Journal of Neuroscience 2001, 21:RC143.
34. Fuxe K., Agnati L.F., Jacobsen K., Hillion J., Canals M., Torvinen M., et al. Receptor heteromerization in adenosine A2A receptor signaling: relevance for striatal function and Parkinson's disease. Neurology 2003, 61:19-23.
35. Ferré S., Quiroz C., Woods A.S., Cunha R., Popoli P., Ciruela F., et al. An update on adenosine A2A-dopamine D2 receptor interactions: implications for the function of G protein-coupled repcetors. Current Pharmaceutical Design 2008, 14:1468-1474.
36. Hauber W., Neuscheler P., Nagel J., Müller C.E. Catalepsy induced by a blockade of dopamine D1 or D2 receptors was reversed by a concomitant blockade of adenosine A2A receptors in the caudate putamen of rats. European Journal of Neuroscience 2001, 14:1287-1293.
37. Ferré S., Ciruela F., Canals M., Marcellino D., Burgueno J., Casado V., et al. Adenosine A2A-dopamine D2 receptor-receptor heteromers. Targets for neuro-psychiatric disorders. Parkinsonism & Related Disorders 2004, 10:265-271.
38. Ishiwari K., Madson L.J., Farrar A.M., Mingote S.M., Valenta J.P., DiGianvittorio M.D., et al. Injections of the selective adenosine A2A antagonist MSX-3 into the nucleus accumbens core attenuate the locomotor suppression induced by haloperidol in rats. Behavioural Brain Research 2007, 178:190-199.
39. Salamone J.D., Ishiwari K., Betz A.J., Farrar A.M., Mingote S.M., Font L., et al. Dopamine/adenosine interactions related to locomotion and tremor in animal models: possible relevance to parkinsonism. Parkinsonism & Related Disorders 2008, 2:130-134.
40. Salamone J.D., Betz A.J., Ishiwari K., Felsted J., Madson L., Mirante B., et al. Tremorolytic effects of adenosine A2A antagonists: implications for parkinsonism. Frontiers in Bioscience 2008, 13:3594-3605.
41. Varty G.B., Hodgson R.A., Pond A.J., Grzelak M.E., Parker E.M., Hunter J.C. The effects of adenosine A2A receptor antagonists on haloperidol-induced movement disorders in primates. Psychopharmacology 2008, 200:393-401.
42. Betz A.J., Vontell R., Valenta J., Worden L., Sink K.S., Font L., et al. Effects of the adenosine A(2A) antagonist KW-6002 (istradefylline) on pimozide-induced oral tremor and striatal c-Fos expression: Comparisons with the muscarinic antagonist tropicamide. Neuroscience 2009, 163:97-108.
43. Ferré S. An update on the mechanisms of the psychostimulant effects of caffeine. Journal of Neurochemistry 2008, 105:1067-1079.
44. Reissig C.J., Strain E.C., Griffiths R.R. Caffeinated energy drinks-a growing problem. Drug and Alcohol Dependence 2009, 99:1-10.
45. Farrar A.M., Pereira M., Velasco F., Hockemeyer J., Muller C.E., Salamone J.D. Adenosine A(2A) receptor antagonism reverses the effects of dopamine receptor antagonism on instrumental output and effort-related choice in the rat: implications for studies of psychomotor slowing. Psychopharmacology 2007, 191:579-586.
46. Farrar A.M., Segovia K.N., Randall P.A., Nunes E.J., Collins L.E., Stopper C.M., et al. Nucleus accumbens and effort-related functions: behavioral and neural markers of the interactions between adenosine A2A and dopamine D2 receptors. Neuroscience 2010, 166:1056-1067.
47. Salamone J.D., Correa M., Farrar A., Mingote S.M. Effort-related functions of nucleus accumbens dopamine and associated forebrain circuits. Psychopharmacology 2007, 191:461-482.
48. Salamone J.D., Farrar A.M., Font L., Patel V., Schlar D.E., Nunes E.J., et al. Differential actions of Adenosine A1 and A2A antagonists on the effort-related effects of dopamine D2 antagonism. Behavioural Brain Research 2009, 201:216-222.
49. Salamone J.D., Correa M., Farrar A.M., Nunes E.J., Collins L.E. The role of dopamine-adenosine interactions in the brain circuitry regulating effort related decision making: insights into pathological aspects of motivation. Future Neurology 2010, 5:377-392.
50. Mott A.M., Nunes E.J., Collins L.E., Port R.G., Sink K.S., Hockemeyer J., et al. The adenosine A(2A) antagonist MSX-3 reverses the effects of the dopamine antagonist haloperidol on effort-related decision making in a T-maze cost/benefit procedure. Psychopharmacology 2009, 204:103-112.
51. Nunes E.J., Randall P.A., Santerre J.L., Given A.B., Sager T.N., Correa M., et al. Differential effects of selective adenosine antagonists on the effort-related impairments induced by dopamine D1 and D2 antagonism. Neuroscience 2010, 170:269-280.
52. Pardo M., López-Cruz L., Valverde O., Ledent C., Baqi Y., Müller C.E., et al. Adenosine A(2A) receptor antagonism and genetic deletion attenuate the effects of dopamine D(2) antagonism n effort-based decision making in mice. Neuropharmacology 2012, 62:2068-2077.
53. Heinz A., Knable M.B., Coppola R., Gorey J.G., Jones D.W., Lee K.S., et al. Psychomotor slowing, negative symptoms and dopamine receptor availability-an IBZM SPECT study in neuroleptic-treated and drug-free schizophrenic patients. Schizophrenia Research 1998, 31:19-26.
54. McKerchar T.L., Fowler S.C. Dissimilar effects of subchronic clozapine and haloperidol on operant lever pressing in C57BL/6J, BALB/cJ, and LP/J mice. Behavioural Pharmacology 2005, 16:585-589.
55. López-Cruz L., Pardo M., Dosda A., Salamone J.D., Correa M. Comparison between high doses of caffeine and theophylline on motor and anxiogenic effects in CD1 mice: studies of acute and chronic administration. Behavioural Pharmacology 2011, 22:71-72.
56. Ledent C., Vaugeois J.M., Schiffmann S.N., Pedrazzini T., El Yacoubi M., Vanderhaeghen J.J., et al. Agressiveness, hipoalgesia and high blood pressure in mice lacking the adenosine A2a receptor. Nature 1997, 388:674-678.
57. Soria G., Castañé A., Ledent C., Parmentier M., Maldonado R., Valverde O. The lack of A2A adenosine receptors diminishes the reinforcing efficacy of cocaine. Neuropsychopharmacology 2006, 31:978-987.
58. Hockemeyer J., Burbiel J.C., Müller C.E. Multigram-scale syntheses, stability, and photoreactions of A2A adenosine receptor antagonists with 8-styrylxanthine structure: potential drugs for Parkinson's disease. Journal of Organic Chemistry 2004, 69:3308-3318.
59. Keppel G. Design and analysis: A researcher's handbook 1991, Prentice-Hall, Englewood Cliffs, New Jersey.
60. Ishiwari K., Weber S.M., Mingote S., Correa M., Salamone J.D. Accumbens dopamine and the regulation of effort in food-seeking behavior: modulation of work output by different ratio or force requirements. Behavioural Brain Research 2004, 151:83-91.
61. Fujiwara H. Comparative studies of sulpiride and classical neuroleptics on induction of catalepsy, locomotor activity, and brain dopamine metabolism in mice. Pharmacology Biochemistry and Behavior 1992;41:301-8.
62. Malec D., Poleszak E. Involvement of adenosine receptors in dizocilpine-induced motor activity in mice. Pharmacological Reports 2006, 58:101-106.
63. Zhang Q., Yu Y.P., Ye Y.L., Zhang J.T., Zhang W.P., Wei W.Q. Spatiotemporal properties of locomotor activity after administration of central nervous stimulants and sedatives in mice. Pharmacology Biochemistry and Behavior 2011, 97:577-585.
64. Bishnoi M., Chopra K., Kulkarni S.K. Theophylline, adenosine receptor antagonist prevents behavioral, biochemical and neurochemical changes associated with an animal model of tardive dyskinesia. Pharmacological Reports 2007, 59:181-191.
65. Trevitt J., Vallance C., Harris A., Goode T. Adenosine antagonists reverse the cataleptic effects of haloperidol: implications for the treatment of Parkinson's disease. Pharmacology Biochemistry and Behavior 2009, 92:521-527.
66. Maemoto T., Finlayson K., Olverman H.J., Akahane A., Horton R.W., Butcher S.P. Species differences in brain adenosine A1 receptor pharmacology revealed by use of xanthine and pyrazolopyridine based antagonists. British Journal of Pharmacology 1997, 122:1202-1208.
67. Hsu C.W., Chen C.Y., Wang C.S., Chiu T.H. Caffeine and a selective adenosine A2A receptor antagonist induce reward and sensitization behavior associated with increased phospho-Thr75-DARPP-32 in mice. Psychopharmacology 2009, 204:313-325.
68. Lerner T.N., Horne E.A., Stella N., Kreitzer A.C. Endocannabinoid signaling mediates psychomotor activation by adenosine A2A antagonists. Journal of Neuroscience 2010, 30:2160-2164.
69. Marcellino D., Lindqvist E., Schneider M., Müller C.E., Fuxe K., Olson L., et al. Chronic A2A antagonist treatment alleviates parkinsonian locomotor deficiency in MitoPark mice. Neurobiology of Disease 2010, 40:460-466.
70. Kachroo A., Orlando L.R., Grandy D.K., Chen J.F., Young A.B., Schwarzschild M.A. Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice. Journal of Neuroscience 2005, 25:10414-10419.
71. Belke T., Dunbar M. Effects of fixed-interval schedule and reinforce duration on responding by the opportunity to run. Journal of the Experimental Analysis of Behavior 1998, 70:69-78.
72. Randall P.A., Nunes E.J., Janniere S.L., Stopper C.M., Farrar A.M., Sager T.N., et al. Stimulant effects of adenosine antagonists on operant behavior: differential actions of selective A2A and A1 antagonists. Psychopharmacology 2011, 216:173-186.
73. El Yacoubi M., Ledent C., Menard J.F., Parmentier M., Costentin J., Vaugeois J.M. The stimulant effects of caffeine on locomotor behaviour in mice are mediated through its blockade of adenosine A(2A) receptors. British Journal of Pharmacology 2000, 129:1465-1473.
74. Yang J.N., Chen J.F., Fredholm B.B. Physiological roles of A1 and A2A adenosine receptors in regulating heart rate, body temperature, and locomotion as revealed using knockout mice and caffeine. American Journal of Physiology. Heart and Circulatory Physiology 2009, 296:1141-1149.
75. Lazarus M., Shen H.Y., Cherasse Y., Qu V.V.M., Huang Z.L., Bass C.E., et al. Arousal effect of caffeine depends on adenosine A2A receptors in the shell of the nucleus accumbens. Journal of Neuroscience 2011, 31:10067-10075.
76. Johansson B., Svenningsson P., Adén U., Lindström K., Fredholm B.B. Evidence that the increase in striatal c-fos following acute high-dose caffeine is not due to direct interaction with striatal adenosine receptors. Acta Physiologica Scandinavica 1992, 146:539-541.
77. Svenningsson P., Johansson B., Fredholm B.B. Effect of different xanthines and phosphodiesterase inhibitors on c-fos expression in rat striatum. Acta Physiologica Scandinavica 1995, 154:17-24.
78. Dassesse D., Vanderwinden J.M., Goldberg I., Vanderhaeghen J.J., Schiffmann S.N. Caffeine-mediated induction of c-fos, zif-268 and arc expression through A1 receptors in the striatum: different interactions with the dopaminergic system. European Journal of Neuroscience 1999, 11:3101-3114.
79. Pinna A., Wardas J., Cozzolino A., Morelli M. Involvement of adenosine A2A receptors in the induction of c-fos expression by clozapine and haloperidol. Neuropsychopharmacology 1999, 20:44-51.
80. Ward R.P., Dorsa D.M. Molecular and behavioral effects mediated by Gs-coupled adenosine A2a, but not serotonin 5-HT4 or 5-HT6 receptors following antipsychotic administration. Neuroscience 1999, 89:927-938.
81. Santerre J.L., Nunes E.J., Kovner R., Leser C.E., Randall P.A., Collins-Praino L.E., et al. The novel adenosine A(2A) antagonist prodrug MSX-4 is effective in animal models related to motivational and motor functions. Pharmacology Biochemistry and Behavior 2012, 102:477-487.
82. Marsden C.D., Duvoisin R.C., Jenner P., Parkers J.D., Pycock C., Tarsy D. Relationship between animal models and clinical parkinsonism. Advances in Neurology 1975, 9:165-175.
83. Salamone J.D., Correa M. The mysterious motivational functions of mesolimbic dopamine. Neuron 2012, 76:470-485.